• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • About Us
  • Our Laboratory
  • Contact Us
NPS Discovery
  • Reports
    • NPS Discovery Dashboard
    • Monographs
    • Trend Reports
    • Public Alerts
    • NPS Scope Recommendations
    • Drug Checking
    • Clinical Reports
    • NPS Discovery Toolkits
  • Resources
    • Publications
    • Presentations
    • Helpful Links
    • NPS in the News
  • CFSRE
Home Public Health Alert New Systematic Naming for Synthetic Cannabinoid “MDA-19” and Its Related Analogues: BZO-HEXOXIZID, 5F-BZO-POXIZID, and BZO-POXIZID

New Systematic Naming for Synthetic Cannabinoid “MDA-19” and Its Related Analogues: BZO-HEXOXIZID, 5F-BZO-POXIZID, and BZO-POXIZID

August 31, 2021

Cayman Chemical and NPS Discovery at the Center for Forensic Science Research and Education (CFSRE) have developed new, more appropriate names to address the newly emergent “MDA-19” and its related analogues following the systematic convention typically used for synthetic cannabinoid nomenclature.

Synthetic cannabinoids represent a vastly diverse sub-class of novel psychoactive substances (NPS). The turnover of this sub-class is largely linked to drug scheduling actions and, like other sub-classes of NPS, new drugs were historically produced via slight tweaks to the molecular structure. In May 2021, China announced new legislation to control synthetic cannabinoids as a class using commonly encountered structural backbones. This has resulted in the emergence of new generations of synthetic cannabinoids with core components that were previously unencountered and/or not well characterized. An example is “MDA-19” and its related analogues. “MDA-19” is a CB2 agonist and was studied, like many synthetic cannabinoids, under legitimate research for pharmaceutical purposes. Similar to JWH-018 and other early synthetic cannabinoids, naming conventions utilizing the initials of a researcher or organization are not ideal and may be misleading (e.g., the abbreviation “MDA” is also used for the stimulant drug methylenedioxyamphetamine). A well-accepted systematic naming convention exists for synthetic cannabinoids and should be applied, where appropriate, to avoid any confusion or mischaracterization.

CLICK HERE TO ACCESS REPORT

Tags: Convention, Forensic, MDA-19, Naming, Nomenclature, NPS, OXIZID, synthetic cannabinoid, Toxicology

Reader Interactions

sidebar

Popular Tags

  • Public Health
  • overdose
  • Toxicology
  • Adulterant
  • Forensic
  • NPS
  • Clinical
  • Drug
  • Fentanyl
  • opioid
  • Emergency Department
  • drugs
  • Chemistry
  • Heroin
  • Synthetic
  • philadelphia
  • Toxic
  • Postmortem
  • Opioids
  • Synthetic Opioid

Meet Our Scientists

Alex J. Krotulski, PhD
Associate Director & Program Manager

Mandi L.A. Mohr, MSFS, D-ABFT-FT
Associate Director

Melissa F. Fogarty, MSFS, D-ABFT-FT
Laboratory Manager

Sara E. Walton, BS
Forensic Science Technician

Barry K. Logan, PhD, F-ABFT
Executive Director

Email Us At

npsdiscovery@cfsre.org

Contact Us

  • npsdiscovery@frfoundation.org
  • 215-366-1591

About Us

Newsroom

Follow Us


© 2022 The Center for Forensic Science Research & Education
  • Privacy Policy
  • Terms of Use
  • Sitemap